Compound class:
Synthetic organic
Comment: Compound 37 [PMID: 29193967] is a potent, orally bioavailable PLA2-G7 (Lp-PLA2) inhibitor. Structurally it is has a novel sulfonamide scaffold, and is a candidate for further optimisation. Compounds of different chemotypes are being explored as tools to examine the pharmacological modulation of PLA2-G7 as a target for clinical intervention- see also darapladib (failed Phase 3 trial in coronary heart disease), rilapladib (completed Phase 2 for Alzheimer's disease) and (S)-23 [PMID: 27933945] (tool compound).
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Compound 37 exhibits good inhibitory activity, favourable oral bioavailability and in vivo activity [1]. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|